These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 8375020

  • 1. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.
    Bremner JC.
    Cancer Metastasis Rev; 1993 Jun; 12(2):177-93. PubMed ID: 8375020
    [Abstract] [Full Text] [Related]

  • 2. Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.
    Bremner JC, Adams GE, Pearson JK, Sansom JM, Stratford IJ, Bedwell J, Bown SG, MacRobert AJ, Phillips D.
    Br J Cancer; 1992 Dec; 66(6):1070-6. PubMed ID: 1457346
    [Abstract] [Full Text] [Related]

  • 3. A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour.
    Wood PJ, Horsman MR, Khalil AA, Steinberg F, Streffer C, Overgaard J, Stratford IJ, Adams GE.
    Acta Oncol; 1996 Dec; 35(8):989-94. PubMed ID: 9023383
    [Abstract] [Full Text] [Related]

  • 4. Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
    Bremner JC, Bradley JK, Adams GE, Naylor MA, Sansom JM, Stratford IJ.
    Int J Radiat Oncol Biol Phys; 1994 May 15; 29(2):329-32. PubMed ID: 8195028
    [Abstract] [Full Text] [Related]

  • 5. Bioreductive drugs and the selective induction of tumour hypoxia.
    Bremner JC, Stratford IJ, Bowler J, Adams GE.
    Br J Cancer; 1990 May 15; 61(5):717-21. PubMed ID: 2110814
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
    Butler SA, Wood PJ, Cole S, Williams C, Adams GE, Stratford IJ.
    Br J Cancer; 1997 May 15; 76(4):438-44. PubMed ID: 9275019
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours.
    Patterson AV, Williams KJ, Cowen RL, Jaffar M, Telfer BA, Saunders M, Airley R, Honess D, van der Kogel AJ, Wolf CR, Stratford IJ.
    Gene Ther; 2002 Jul 15; 9(14):946-54. PubMed ID: 12085243
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.
    Koch CJ.
    Cancer Res; 1993 Sep 01; 53(17):3992-7. PubMed ID: 8358728
    [Abstract] [Full Text] [Related]

  • 11. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
    Adams GE, Stratford IJ, Edwards HS, Bremner JC, Cole S.
    Int J Radiat Oncol Biol Phys; 1992 Sep 01; 22(4):717-20. PubMed ID: 1544844
    [Abstract] [Full Text] [Related]

  • 12. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
    Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliott W, Suto M, Sebolt-Leopold J.
    Int J Radiat Oncol Biol Phys; 1992 Sep 01; 22(3):545-8. PubMed ID: 1735694
    [Abstract] [Full Text] [Related]

  • 13. Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro.
    Naylor MA, Threadgill MD, Showalter HD, Stratford IJ, Stephens MA, Fielden EM, Adams GE.
    Drug Des Discov; 1993 Sep 01; 10(3):249-55. PubMed ID: 8268395
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of oncogenicity for bioreductive drugs.
    Hei TK, Piao CQ, He ZY, Hall EJ.
    Int J Radiat Oncol Biol Phys; 1992 Sep 01; 22(4):747-50. PubMed ID: 1544847
    [Abstract] [Full Text] [Related]

  • 15. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
    Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC.
    Radiat Res; 1990 Oct 01; 124(1 Suppl):S38-43. PubMed ID: 2236508
    [Abstract] [Full Text] [Related]

  • 16. Metabolism and radiosensitization of 4,5-dimethylmisonidazole, a ring-substituted analog of misonidazole.
    Born JL, Smith BR, Harper N, Koch CJ.
    Biochem Pharmacol; 1992 Mar 17; 43(6):1337-44. PubMed ID: 1562284
    [Abstract] [Full Text] [Related]

  • 17. Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.
    Lunt SJ, Telfer BA, Fitzmaurice RJ, Stratford IJ, Williams KJ.
    Clin Cancer Res; 2005 Jun 01; 11(11):4212-6. PubMed ID: 15930359
    [Abstract] [Full Text] [Related]

  • 18. RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions.
    Stratford IJ, O'Neill P, Sheldon PW, Silver AR, Walling JM, Adams GE.
    Biochem Pharmacol; 1986 Jan 01; 35(1):105-9. PubMed ID: 3753579
    [No Abstract] [Full Text] [Related]

  • 19. Enhancement of artificial lung metastases by misonidazole.
    Rockwell S, Nierenburg M, Irvin CG.
    Int J Radiat Oncol Biol Phys; 1984 Aug 01; 10(8):1395-8. PubMed ID: 6469763
    [Abstract] [Full Text] [Related]

  • 20. Newly synthesized hypoxia-mediated drugs as radiosensitizers and cytotoxic agents.
    Astor M, Hall EJ, Biaglow JE, Parham JC.
    Int J Radiat Oncol Biol Phys; 1982 Jan 01; 8(1):75-83. PubMed ID: 7061257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.